Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 201

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

TAMOXIFEN VERSUS PLACEBO IN THE TREATMENT OF PEYRONIE’S DISEASE

TELOKEN, CLAUDIO, RHODEN, ERNANI LUIS, GRAZZIOTIN, TÚLIO MEYER, DA ROS, CARLOS TEODÓSIO, SOGARI, PAULO ROBERTO, SOUTO, CARLOS ARY VARGAS · 1999 · Journal of Urology

Abstract

PURPOSE: We evaluated the effects of oral tamoxifen and placebo in patients with Peyronie's disease. MATERIALS AND METHODS: We selected 25 patients with Peyronie's disease who did not have calcified plaque for treatment in the andrology outpatient clinic. A medical history was obtained, and physical examination, penile x-ray, penile ultrasound and pharmacologically induced erection with prostaglandin E1 were performed. Patients were randomly divided into group 1--those who received 20 mg. tamoxifen twice daily for 3 months and group 2--those who received placebo for the same period. The same evaluations were done 4 months later and results were compared. Qualitative (chi-square test) and quantitative (Student's t test) results were analyzed using the Yates correction factor with p <0.05 considered significant. RESULTS: Pain subsided in 66.6 and 75% of the patients treated with tamoxifen and placebo, respectively (p >0.05). In groups 1 and 2 a reduction in the penile deformity was noticed by 46.1 and 41.7% of the patients (p >0.05), and a decrease in plaque size was noticed by 30.7 and 25%, respectively. On the other hand, objective measurements did not reveal any difference in plaque area or curvature angle. CONCLUSIONS: This study did not show significant improvement in pain, curvature or plaque size in patients with Peyronie's disease who were treated with tamoxifen compared with those treated with placebo.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0022-5347(05)68087-1

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 201

Metadata

Authors
TELOKEN, C., RHODEN, E. L., GRAZZIOTIN, T. M., DA ROS, C. T., SOGARI, P. R., & SOUTO, C. A. V.
Venue
Journal of Urology
Published
1999-12
Volume
162
Issue
6
Pages
2003-2005
ISSN
  • 0022-5347 (ISSN-L)
  • 1527-3792
OpenAlex
W2068127169
Cited by
201
References
1
FWCI
2.39
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TAMOXIFEN VERSUS PLACEBO IN THE TREATMENT OF PEYRONIE’S DISEASE. https://app.cochat.ai/papers/10.1016/s0022-5347(05)68087-1
The paper
TELOKEN, C., RHODEN, E. L., GRAZZIOTIN, T. M., DA ROS, C. T., SOGARI, P. R., & SOUTO, C. A. V. (1999). TAMOXIFEN VERSUS PLACEBO IN THE TREATMENT OF PEYRONIE’S DISEASE. Journal of Urology. https://doi.org/10.1016/s0022-5347(05)68087-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.